ArticleThe American journal of pathology1996
Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma.
Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 89 citations in OpenAlex.
- Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma.Upsala journal of medical sciences · 2023Article
- Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?Frontiers in oncology · 2022Review
- Mechanism of Mucin Recognition by Lectins: A Thermodynamic Study.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Expression levels of β-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study.Cancer biology & medicine · 2017Article
- Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness.Annals of translational medicine · 2014Review
- Why anti-Bcl-2 clinical trials fail: a solution.Cancer metastasis reviews · 2014Review
- Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence.World journal of urology · 2013Article
- Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.Pharmaceutical research · 2012Review
- Isolation of galectin-1 from human platelets: its interaction with actin.The protein journal · 2012Article
- Galectins as cancer biomarkers.Cancers · 2010Article
- Thermodynamics of multivalent carbohydrate-lectin cross-linking interactions: importance of entropy in the bind and jump mechanism.Biochemistry · 2009Article
- Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources.Glycoconjugate journal · 2007Article
- The role of galectin-3 in cancer drug resistance.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2007Review
- New roles for galectins in brain tumors--from prognostic markers to therapeutic targets.Brain pathology (Zurich, Switzerland) · 2005Review
- An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas.The American journal of pathology · 2004Article
- Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype.Leukemia · 2003Article
- Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells.Oncogene · 2002Article
- Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide.The American journal of pathology · 2002Article
- Galectin-3 and metastasis.Glycoconjugate journal · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Galectin-3 is a member of a newly named family of beta-galactoside-binding animal lectins, which has been described with a number of possible important biological functions, including the regulation of cell growth and association with tumor transformation. This protein has a wide tissue distribution but is notably not expressed by normal lymphocytes. We have previously shown that galectin-3 is markedly up-regulated in HTLV-I-infected T cells, most likely mediated by the viral transactivating protein Tax. In this study, we surveyed various lymphomas by immunohistochemistry and found the expression of galectin-3 in all of the 8 cases of Ki-1+ anaplastic large-cell lymphoma (ALCL). Immunoreactivity for galectin-3 was found in a majority of the neoplastic cells in the ALCLs studied. In contrast, only 2 of the 35 cases of other types of lymphoma, including various Hodgkin's and non-Hodgkin's lymphomas, were positive. Unlike the cases of ALCL, immunoreactivity for galectin-3 in these 3 cases was found only sporadically in a small number of neoplastic cells. Thus, galectin-3 may prove to be a useful marker for ALCL and its expression in neoplastic cells in ALCL may contribute to the biological behavior of this specific type of lymphoma.
Indexed as
Identifiers
8546213PMC1861589W1860931201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.